Patrick Machado

Patrick Machado founded Medivation, Inc. in 1995, where he worked as Director from 2014 to 2016 and Medivation LLC (California) in 1995, where he worked as Director from 2014 to 2016.
Mr. Machado also currently works at Adverum Biotechnologies, Inc., as Chairman from 2019, Prota Therapeutics Pty Ltd., as Chairman, Xenon Pharmaceuticals, Inc., as Independent Director from 2020, Arcus Biosciences, Inc., as Independent Director from 2019, Auransa, Inc., as Director, Alumis, Inc., as Independent Director from 2024, and Avenzo Therapeutics, Inc., as Director.
Mr. Machado also formerly worked at Armaron Bio Ltd., as Chairman, Inotek Pharmaceuticals Corp., as Independent Director from 2016 to 2018, ACELYRIN, Inc., as Independent Director from 2021 to 2025, Principia Biopharma, Inc., as Director from 2019 to 2020, Turning Point Therapeutics, Inc., as Independent Director from 2019 to 2022, Roivant Sciences Ltd., as Independent Director from 2016 to 2022, Endocyte, Inc., as Independent Director in 2018, Medivation Neurology LLC, as Chief Financial Officer, Director & Senior VP from 2003 to 2004, Roivant Sciences, Inc., as Director, Sio Gene Therapies, Inc., as Director from 2017 to 2018, Axovant Sciences, Inc., as Director from 2017 to 2018, Montes Archimedes Acquisition Corp., as Independent Director, Turnstone Biologics Corp., as Independent Director from 2018 to 2024, Therachon AG, as Director in 2019, Chimerix, Inc., as Independent Director from 2014 to 2024, SCYNEXIS, Inc., as Independent Director from 2015 to 2019, Chiron Corp., as Chief Legal Counsel, Orion Acquisition Corp.
II, as Chief Financial Officer, Cytyc Corp., as Consultant in 2002, Morrison & Foerster LLP, as Principal, Pro-Duct Health, Inc., as Chief Financial Officer & Senior Vice President from 2000 to 2001, and Therachon Holding GmbH, as Member-Supervisory Board.
Mr. Machado received his undergraduate degree in 1986 from Santa Clara University and graduate degree in 1989 from Harvard Law School.